An antibody cocktail from Regeneron has been approved by the FDA as the first treatment for Ebola, offering hope that the same approach could be used to combat COVID-19.

Regeneron’s antibody cocktail is the latest COVID-19 drug to receive Emergency Use Authorization in the US, becoming the first therapy of this kind to become available.

Valued at a market cap of $82.9 billion, Regeneron Pharmaceuticals ... and Zaltrap and is also known for developing an antibody cocktail for COVID-19, called REGEN-COV. Companies valued at ...